DNA Microarray Global Market Report 2024

The DNA microarray market size has grown rapidly in recent years. It will grow from $3.02 billion in 2023 to $3.38 billion in 2024 at a compound annual growth rate (CAGR) of 12%. Historical growth can be credited to pharmacogenomics, healthcare infrastructure advancements, collaborative efforts, cost-cutting measures, and enhanced public awareness and education.

The DNA microarray market size is expected to see rapid growth in the next few years. It will grow to $5.34 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. In the forecasted period, growth is anticipated due to the expansion of personalized medicine, the rise of comparative genomic hybridization (CGH), increased focus on agricultural genomics, regulatory approvals and standardizations, and the escalating prevalence of chronic illnesses. Key trends in the forecasted period encompass progress in genomic research, augmented funding for genomic endeavors, technological breakthroughs, integration with complementary technologies, and advancements in technology.

The rapid adoption of personalized medicine is a key factor fueling the growth of the DNA microarray market. Personalized medicine tailors medical treatments to individual patients, considering their genetic, environmental, and lifestyle factors to enhance treatment effectiveness. This approach has gained prominence due to advancements in 'omics' technology, genetics, and data integration, recognizing the significance of personalized medications and preventive measures. DNA microarrays are pivotal in personalized medicine, analyzing gene expression patterns to devise customized treatment approaches based on an individual's genetic composition. Notably, in February 2024, the FDA approved 16 new personalized therapies for rare diseases, a substantial increase from the 6 approved in 2022, according to the Personalized Medicine Coalition, a US-based non-profit organization. Thus, the swift adoption of personalized medicine serves as a driving force behind the expansion of the DNA microarray market.

Leading companies in the DNA microarray market are concentrating on developing advanced technology that offers a turnaround time of just two days to gain a competitive advantage. Microarray analysis with a two-day turnaround time ensures prompt and efficient results, accelerating both research and clinical decision-making processes. For instance, in August 2023, Thermo Fisher Scientific Inc., a US-based biotechnology firm, introduced the Applied Biosystems CytoScan HD Accel array. This new chromosomal microarray enhances productivity, efficiency, and profitability in cytogenetic research labs with its industry-leading two-day turnaround time. The CytoScan HD Accel array enables whole-genome analysis with improved coverage in over 5,000 key genomic regions, providing insights into chromosomal variants for various applications in prenatal, postnatal, and oncology research.

In October 2021, SCHOTT AG, a Germany-based manufacturer of glass and glass ceramics, acquired Applied Microarray Inc. for an undisclosed sum. This acquisition is expected to bolster SCHOTT's ability to offer a comprehensive contract manufacturing solution for point-of-care microarray consumables, particularly in areas such as infectious disease detection. Applied Microarray Inc., based in the US, specializes in providing DNA microarrays.

Major companies operating in the DNA microarray market are Roche Holding AG, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., bioMérieux SA, Schott AG, Bio-Rad Laboratories Inc., QIAGEN N.V., Bioneer Corporation, CapitalBio Technology Co. Ltd., Eurofins Genomics LLC, Savyon Diagnostics Ltd., Oxford Gene Technology, Sengenics Corporation LLC, Affymetrix, BioCat GmbH, Scienion AG, LC Sciences, Arrayit Corporation, Akonni Biosystems Inc., Arraystar Inc., Febit Holding GmbH.

North America was the largest region in the DNA microarray market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the DNA microarray market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the DNA microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A DNA microarray is a potent instrument utilized in molecular biology to concurrently gauge the expression levels of numerous genes. It comprises small spots, termed probes, which contain established DNA sequences fixed onto a solid surface. When a sample containing DNA labeled with fluorescence is administered to the microarray, the fluorescence intensity at each spot reflects the expression level of the corresponding gene. This enables researchers to scrutinize gene expression patterns and pinpoint biomarkers linked with diverse diseases or experimental conditions.

The primary categories of DNA microarrays encompass complementary DNA microarrays, oligonucleotide DNA microarrays, and other variations. Complementary DNA serves as a robust research aid for assessing gene expression levels across a broad array of genes simultaneously. These microarrays find utility in gene expression analysis, genotyping, and various other applications, and are utilized by various end-users, predominantly pharmaceutical and biotechnology firms, diagnostic facilities, medical institutions, academic and research establishments, among others.

The DNA microarray market research report is one of a series of new reports that provides DNA microarray market statistics, including DNA microarray industry global market size, regional shares, competitors with a DNA microarray market share, detailed DNA microarray market segments, market trends and opportunities, and any further data you may need to thrive in the DNA microarray industry. This DNA microarray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The DNA microarray market consists of sales of DNA microarray chips, microarray scanners, and microarray printers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.